<DOC>
	<DOCNO>NCT00027300</DOCNO>
	<brief_summary>The purpose study determine safety efficacy natalizumab treatment individual diagnose relapse remit multiple sclerosis ( MS ) . It hop natalizumab prevent certain type white blood cell move bloodstream organ , include brain , damage autoimmune disease ( disease body 's immune system attack certain organ ) . These white blood cell think cause inflammation result lesion ( small area damage ) brain . These lesion think cause relapse disability MS .</brief_summary>
	<brief_title>Safety Efficacy Natalizumab Treatment Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Diagnosis MS , define McDonald et al. , criterion # 14 ( McDonald et al. , 2001 ) Between age 18 50 , inclusive . Baseline EDSS score 0.0 5.0 , inclusive . Have experience least one relapse within 12 month prior randomization . Cranial MRI scan demonstrate lesion ( ) consistent MS. Have give write informed consent participate study . Primary progressive , secondary progressive , progressive relapse MS. MS relapse occur , opinion investigator , within 50 day prior randomization and/or subject stabilize previous relapse . A clinically significant infectious illness within 30 day prior randomization . History , abnormal laboratory result indicative significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , gastrointestinal , dermatologic , psychiatric , renal and/or major disease , opinion investigator , would preclude administration recombinant humanize antibody immunomodulating agent 116 week . History severe allergic anaphylactic reaction know drug hypersensitivity . Unable perform Timed 25foot Walk , 9HPT , PASAT 3 . Abnormal blood test perform Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
</DOC>